Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: The Brazilian experience in the past decade

Leukemia Research

Volumn 28, Issue 9, 2004, Pages 933-939

  Valera, Elvis Terci ^a   Latorre, Maria Do Rosário Dias ^a   Mendes, Wellington Luiz ^b   Seber, Adriana ^c   Lee, Maria Lucia Martino ^c   De Paula, Mario José Aguiar ^d   Loggetto, Sandra Regina ^e   Velloso, Elvira ^a   Niero Melo, Ligia ^a   Lopes, Luiz Fernando ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b IM IN JK) Inst Do C   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Oncology Institute   (Brazil)

^e Hematology Service   (Brazil)

Author keywords

Children; Myelodysplastic syndromes; Neoplasm; Treatment

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; GRAFT REJECTION; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LOW DRUG DOSE; MEDICAL INFORMATION; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

EID: 3242658930     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.01.008     Document Type: Article

References (22)

1. Smith FO, Woods WG. Myeloproliferative and myelodysplastic disorders. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 615-36.
2. Emanuel P.D. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br. J. Hematol. 105:1999;852-863
3. Hiddemann W., Jahns-Streubel G., Verbeek W., Wormann B., Haase D., Schoch C. Intensive therapy for standard-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities. Leuk. Res. 22:1998;S23-S26
4. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndrome. Hematology 2002;136-161.
5. Lopes L.F., Lorand-Metze I., Niero-Melo L., Tone L.G., Velloso E., Campanaro C.M., et al. The Brazilian Pediatric Myelodysplastic Cooperative Group strategies: are they relevant to improve educational approach and correct diagnosis? Leuk. Res. 26:2002;637-642
6. Niero-Melo L. Pitfalls in cyto-histology of Pediatric MDS/JMML. In: Lopes LF, Hasle H, editors. Myelodysplastic and myeloproliferative disorders in children. 1st ed. São Paulo: Editora Lemar; 2003. p. 37-48.
7. Hasle H., Niemeyer J.M., Chessells J.M., Baumann I., Bennett J.M., Kerndrup G., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 17:2003;227
8. Cheson B.D. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk. Res. 22:1998;S17-S21
9. Bennett J.M., Kouides P.A., Forman S.J. The Myelodysplastic syndromes: morphology, risk assessment, and clinical management. Int. J. Hematol. 76:2002;228-238
10. Strupp C., Germing U., Alvado M., Misgeld E., Haas R., Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 16:2002;1-6
11. Zorat F., Shetty V., Dutt D., Lisak L., Nascimben F., Allampallam K., et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. 115:2001;881-894
12. Gryn J., Zeigler Z.R., Shadduck R.K., Lister J., Raymond J.M., Sbeitan I., et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk. Res. 26:2002;893-897
13. Kornblith A.B., Herndon J.E. 2nd, Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 20:2002;2441-2452
14. List A.F. New approaches to the treatment of Myelodysplasia. The Oncologist. 7:2002;39-49
15. Donelli A., Chiodino C., Panissidi T., Roncaglia R., Torelli G. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica. 85:2000;1002-1003
16. Sanders J.E., Buckner C.D., Thomas E.D., Fleischer R., Sullivan K.M., Appelbaum F.A., et al. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood. 71(4):1988;1144-1146
17. Guinan E.C., Tarbell N.J., Tantravahi R., Weinstein H.J. Bone marrow transplantation for children with myelodysplastic syndromes. Blood. 73(2):1989;619-622
18. Aricò M., Biondi A., Pui C.-H. Juvenile myelomonocytic leukemia. Blood. 90(2):1997;479-488
19. Luna-Fineman S., Shannon K.M., Atwater S.K., Davis J., Masterson M., Ortega J., et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 93(2):1999;459-466
20. Locatelli F., Niemeyer C., Angelucci E., Bender-Gotze C., Burdach S., Ebell W., et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J. Clin. Oncol. 15(2):1997;566-573
21. Niemeyer C.M., Aricó M., Basso G., Biondi A., Cantú- Rajnoldi A., Creutzig U., et al. Members of the European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 89(10):1997;3534-3543
22. Woods W.G., Barnard D.R., Alonzo T.A., Buckley J.D., Kobrinsky N., Arthur D.C., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J. Clin. Oncol. 20(2):2002;434-440